Literature DB >> 1865808

Experience with calcium antagonists nitrendipine, diltiazem, and verapamil and beta 2-agonist salbutamol in salvaging ischemic skin flaps in rabbits.

H Kawabata1, K R Knight, S A Coe, J A Angus, B M O'Brien.   

Abstract

This study investigated the efficacy of selected agents in the salvage of experimental skin flaps in rabbits after 21 hours of 25 degrees C ischemia. Calcium channel antagonists nitrendipine, diltiazem, and verapamil increased ischemic skin flap survival in rabbits from 33.3% for buffered saline infused controls to 71.4% (P less than 0.05), 71.4% (P less than 0.05), and 50.0% (not significant) respectively. The beta 2-adrenoceptor agonist salbutamol produced an increase in survival to 64.3%, which narrowly missed statistical significance. All four test agents invoked a vasodilatory response (greatest for nitrendipine, diltiazem, and salbutamol), a slight fall in blood pressure, and a small increase in heart rate. It is concluded that the vasodilatory response in the microcirculation of the ischemic flap helped to minimize the risk of occlusion due to thrombosis or cell sludging during reperfusion, thus leading to improved flap survival.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1865808     DOI: 10.1002/micr.1920120303

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  2 in total

1.  The effects of montelukast on random pattern skin flap survival: An experimental study in rats.

Authors:  Kaan Gideroglu; Fahrettin Yilmaz; Fadullah Aksoy; Guler Bugdayci; Husamettin Cakici; Onur Hapa
Journal:  Curr Ther Res Clin Exp       Date:  2008-10

2.  Regulated extravascular microenvironment via reversible thermosensitive hydrogel for inhibiting calcium influx and vasospasm.

Authors:  Binfan Zhao; Yaping Zhuang; Zhimo Liu; Jiayi Mao; Shutong Qian; Qiuyu Zhao; Bolun Lu; Xiyuan Mao; Liucheng Zhang; Yuguang Zhang; Wenguo Cui; Xiaoming Sun
Journal:  Bioact Mater       Date:  2022-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.